NCT05131828View on ClinicalTrials.gov

CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Multiple Sclerosis
Interventions
DRUG

Metformin and clemastine in combination

"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."

DRUG

Placebo

Placebo tablets to match both metformin and clemastine tablets.

Trial Locations (1)

Unknown

Addenbrooke's Hospital, Cambridge

All Listed Sponsors
collaborator

University of Cambridge

OTHER

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER